Syros Pharmaceuticals Inc (NASDAQ:SYRS) saw an uptick in trading volume on Wednesday . 144,840 shares traded hands during mid-day trading, an increase of 90% from the previous session’s volume of 76,307 shares.The stock last traded at $13.41 and had previously closed at $13.55.

A number of research firms recently weighed in on SYRS. Cowen and Company began coverage on shares of Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “outperform” rating for the company. JMP Securities began coverage on shares of Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “outperform” rating and a $22.00 price objective for the company. Wedbush initiated coverage on shares of Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “outperform” rating and a $18.00 price objective for the company. Piper Jaffray Cos. initiated coverage on shares of Syros Pharmaceuticals in a report on Monday, July 25th. They issued an “overweight” rating and a $20.00 target price for the company. Finally, HC Wainwright initiated coverage on shares of Syros Pharmaceuticals in a report on Monday, July 18th. They issued a “neutral” rating and a $10.00 target price for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $17.50.

The stock’s market capitalization is $320.22 million. The company has a 50-day moving average price of $11.65 and a 200 day moving average price of $12.61.

In related news, Director Robert Nelsen bought 400,000 shares of the company’s stock in a transaction dated Wednesday, July 6th. The shares were acquired at an average price of $12.50 per share, with a total value of $5,000,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Redmile Group, Llc bought 432,746 shares of the company’s stock in a transaction dated Wednesday, July 6th. The stock was bought at an average cost of $12.50 per share, for a total transaction of $5,409,325.00. The disclosure for this purchase can be found here.

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.